Ahead of what may be China’s first regulatory approval for a cell therapy, the Chinese joint venture between Juno Therapeutics Inc. and WuXi AppTec Inc., JW Therapeutics Co., Ltd, has listed on the Hong Kong Stock Exchange in the latest initial public offering involving a biotech from the mainland.
China Cell Therapy Party On: $500m+ Raised In JW IPO, Other Rounds
CAR-T Developer Plans US, Europe Expansion
It's been a big week for cell therapy developers in China with well over $500m raised through an IPO and large new funding rounds for several other ventures.
More from Gene Therapies
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?